カテゴリー： QYResearch, 世界, 医療/バイオ

世界の原発性高シュウ酸尿症治療市場インサイト及び予測（経口、静脈内、その他）

◆英語タイトル：Global Primary Hyperoxaluria Treatment Market Insights, Forecast to 2028
	◆商品コード：QY22JLX10477 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2022年7月（※2025年版があります。お問い合わせください。） ◆ページ数：90 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥744,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,117,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,489,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、原発性高シュウ酸尿症治療のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に原発性高シュウ酸尿症治療の世界市場のxxx％を占める「経口」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「タイプ1」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
原発性高シュウ酸尿症治療の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの原発性高シュウ酸尿症治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

原発性高シュウ酸尿症治療のグローバル主要企業には、Oxthera、Dicerna Pharmaceuticals、Allena Pharmaceuticals、Biocodex、Alnylam Pharmaceuticals、Tecoland Corporation、Zhejiang Tianxin Pharmaceutical、Takeda Pharmaceuticals、Wuxi Further Pharmaceuticalなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

原発性高シュウ酸尿症治療市場は、種類と用途によって区分されます。世界の原発性高シュウ酸尿症治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
経口、静脈内、その他

【用途別セグメント】
タイプ1、タイプ2、タイプ3

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 原発性高シュウ酸尿症治療製品概要
- 種類別市場（経口、静脈内、その他）
- 用途別市場（タイプ1、タイプ2、タイプ3）
- 調査の目的
・エグゼクティブサマリー
- 世界の原発性高シュウ酸尿症治療販売量予測2017-2028
- 世界の原発性高シュウ酸尿症治療売上予測2017-2028
- 原発性高シュウ酸尿症治療の地域別販売量
- 原発性高シュウ酸尿症治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別原発性高シュウ酸尿症治療販売量
- 主要メーカー別原発性高シュウ酸尿症治療売上
- 主要メーカー別原発性高シュウ酸尿症治療価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（経口、静脈内、その他）
- 原発性高シュウ酸尿症治療の種類別販売量
- 原発性高シュウ酸尿症治療の種類別売上
- 原発性高シュウ酸尿症治療の種類別価格
・用途別市場規模（タイプ1、タイプ2、タイプ3）
- 原発性高シュウ酸尿症治療の用途別販売量
- 原発性高シュウ酸尿症治療の用途別売上
- 原発性高シュウ酸尿症治療の用途別価格
・北米市場
- 北米の原発性高シュウ酸尿症治療市場規模（種類別、用途別）
- 主要国別の原発性高シュウ酸尿症治療市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの原発性高シュウ酸尿症治療市場規模（種類別、用途別）
- 主要国別の原発性高シュウ酸尿症治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の原発性高シュウ酸尿症治療市場規模（種類別、用途別）
- 主要国別の原発性高シュウ酸尿症治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の原発性高シュウ酸尿症治療市場規模（種類別、用途別）
- 主要国別の原発性高シュウ酸尿症治療市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの原発性高シュウ酸尿症治療市場規模（種類別、用途別）
- 主要国別の原発性高シュウ酸尿症治療市場規模（トルコ、サウジアラビア）
・企業情報
Oxthera、Dicerna Pharmaceuticals、Allena Pharmaceuticals、Biocodex、Alnylam Pharmaceuticals、Tecoland Corporation、Zhejiang Tianxin Pharmaceutical、Takeda Pharmaceuticals、Wuxi Further Pharmaceutical
・産業チェーン及び販売チャネル分析
- 原発性高シュウ酸尿症治療の産業チェーン分析
- 原発性高シュウ酸尿症治療の原材料
- 原発性高シュウ酸尿症治療の生産プロセス
- 原発性高シュウ酸尿症治療の販売及びマーケティング
- 原発性高シュウ酸尿症治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 原発性高シュウ酸尿症治療の産業動向
- 原発性高シュウ酸尿症治療のマーケットドライバー
- 原発性高シュウ酸尿症治療の課題
- 原発性高シュウ酸尿症治療の阻害要因
・主な調査結果

Primary Hyperoxaluria (PH) is a rare genetic disorder caused by deficiencies in glyoxylate metabolism leading to oxalate deposition primarily in kidneys causing end-stage renal disease. It is an inherited autosomal recessive disorder and can be of three types based on the different responsible genes: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). Signs and symptoms may include recurrent kidney stones, hematuria, and urinary tract infections (UTIs).
Market Analysis and Insights: Global Primary Hyperoxaluria Treatment Market
Due to the COVID-19 pandemic, the global Primary Hyperoxaluria Treatment market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Oral accounting for % of the Primary Hyperoxaluria Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Type 1 segment is altered to an % CAGR throughout this forecast period.
China Primary Hyperoxaluria Treatment market size is valued at US$ million in 2021, while the US and Europe Primary Hyperoxaluria Treatment are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Primary Hyperoxaluria Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Primary Hyperoxaluria Treatment include Oxthera, Dicerna Pharmaceuticals, Allena Pharmaceuticals, Biocodex, Alnylam Pharmaceuticals, Tecoland Corporation, Zhejiang Tianxin Pharmaceutical, Takeda Pharmaceuticals and Wuxi Further Pharmaceutical. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Primary Hyperoxaluria Treatment Scope and Segment
Primary Hyperoxaluria Treatment market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Primary Hyperoxaluria Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Oral
Intravenous
Others
Segment by Application
Type 1
Type 2
Type 3
By Company
Oxthera
Dicerna Pharmaceuticals
Allena Pharmaceuticals
Biocodex
Alnylam Pharmaceuticals
Tecoland Corporation
Zhejiang Tianxin Pharmaceutical
Takeda Pharmaceuticals
Wuxi Further Pharmaceutical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Primary Hyperoxaluria Treatment Product Introduction
1.2 Market by Type
1.2.1 Global Primary Hyperoxaluria Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Oral
1.2.3 Intravenous
1.2.4 Others
1.3 Market by Application
1.3.1 Global Primary Hyperoxaluria Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Type 1
1.3.3 Type 2
1.3.4 Type 3
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Primary Hyperoxaluria Treatment Sales Estimates and Forecasts 2017-2028
2.2 Global Primary Hyperoxaluria Treatment Revenue Estimates and Forecasts 2017-2028
2.3 Global Primary Hyperoxaluria Treatment Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Primary Hyperoxaluria Treatment Sales by Region
2.4.1 Global Primary Hyperoxaluria Treatment Sales by Region (2017-2022)
2.4.2 Global Sales Primary Hyperoxaluria Treatment by Region (2023-2028)
2.5 Global Primary Hyperoxaluria Treatment Revenue by Region
2.5.1 Global Primary Hyperoxaluria Treatment Revenue by Region (2017-2022)
2.5.2 Global Primary Hyperoxaluria Treatment Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Primary Hyperoxaluria Treatment Sales by Manufacturers
3.1.1 Global Top Primary Hyperoxaluria Treatment Manufacturers by Sales (2017-2022)
3.1.2 Global Primary Hyperoxaluria Treatment Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Primary Hyperoxaluria Treatment in 2021
3.2 Global Primary Hyperoxaluria Treatment Revenue by Manufacturers
3.2.1 Global Primary Hyperoxaluria Treatment Revenue by Manufacturers (2017-2022)
3.2.2 Global Primary Hyperoxaluria Treatment Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Primary Hyperoxaluria Treatment Revenue in 2021
3.3 Global Primary Hyperoxaluria Treatment Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Primary Hyperoxaluria Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Primary Hyperoxaluria Treatment Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Primary Hyperoxaluria Treatment Sales by Type
4.1.1 Global Primary Hyperoxaluria Treatment Historical Sales by Type (2017-2022)
4.1.2 Global Primary Hyperoxaluria Treatment Forecasted Sales by Type (2023-2028)
4.1.3 Global Primary Hyperoxaluria Treatment Sales Market Share by Type (2017-2028)
4.2 Global Primary Hyperoxaluria Treatment Revenue by Type
4.2.1 Global Primary Hyperoxaluria Treatment Historical Revenue by Type (2017-2022)
4.2.2 Global Primary Hyperoxaluria Treatment Forecasted Revenue by Type (2023-2028)
4.2.3 Global Primary Hyperoxaluria Treatment Revenue Market Share by Type (2017-2028)
4.3 Global Primary Hyperoxaluria Treatment Price by Type
4.3.1 Global Primary Hyperoxaluria Treatment Price by Type (2017-2022)
4.3.2 Global Primary Hyperoxaluria Treatment Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Primary Hyperoxaluria Treatment Sales by Application
5.1.1 Global Primary Hyperoxaluria Treatment Historical Sales by Application (2017-2022)
5.1.2 Global Primary Hyperoxaluria Treatment Forecasted Sales by Application (2023-2028)
5.1.3 Global Primary Hyperoxaluria Treatment Sales Market Share by Application (2017-2028)
5.2 Global Primary Hyperoxaluria Treatment Revenue by Application
5.2.1 Global Primary Hyperoxaluria Treatment Historical Revenue by Application (2017-2022)
5.2.2 Global Primary Hyperoxaluria Treatment Forecasted Revenue by Application (2023-2028)
5.2.3 Global Primary Hyperoxaluria Treatment Revenue Market Share by Application (2017-2028)
5.3 Global Primary Hyperoxaluria Treatment Price by Application
5.3.1 Global Primary Hyperoxaluria Treatment Price by Application (2017-2022)
5.3.2 Global Primary Hyperoxaluria Treatment Price Forecast by Application (2023-2028)
6 North America
6.1 North America Primary Hyperoxaluria Treatment Market Size by Type
6.1.1 North America Primary Hyperoxaluria Treatment Sales by Type (2017-2028)
6.1.2 North America Primary Hyperoxaluria Treatment Revenue by Type (2017-2028)
6.2 North America Primary Hyperoxaluria Treatment Market Size by Application
6.2.1 North America Primary Hyperoxaluria Treatment Sales by Application (2017-2028)
6.2.2 North America Primary Hyperoxaluria Treatment Revenue by Application (2017-2028)
6.3 North America Primary Hyperoxaluria Treatment Market Size by Country
6.3.1 North America Primary Hyperoxaluria Treatment Sales by Country (2017-2028)
6.3.2 North America Primary Hyperoxaluria Treatment Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Primary Hyperoxaluria Treatment Market Size by Type
7.1.1 Europe Primary Hyperoxaluria Treatment Sales by Type (2017-2028)
7.1.2 Europe Primary Hyperoxaluria Treatment Revenue by Type (2017-2028)
7.2 Europe Primary Hyperoxaluria Treatment Market Size by Application
7.2.1 Europe Primary Hyperoxaluria Treatment Sales by Application (2017-2028)
7.2.2 Europe Primary Hyperoxaluria Treatment Revenue by Application (2017-2028)
7.3 Europe Primary Hyperoxaluria Treatment Market Size by Country
7.3.1 Europe Primary Hyperoxaluria Treatment Sales by Country (2017-2028)
7.3.2 Europe Primary Hyperoxaluria Treatment Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Primary Hyperoxaluria Treatment Market Size by Type
8.1.1 Asia Pacific Primary Hyperoxaluria Treatment Sales by Type (2017-2028)
8.1.2 Asia Pacific Primary Hyperoxaluria Treatment Revenue by Type (2017-2028)
8.2 Asia Pacific Primary Hyperoxaluria Treatment Market Size by Application
8.2.1 Asia Pacific Primary Hyperoxaluria Treatment Sales by Application (2017-2028)
8.2.2 Asia Pacific Primary Hyperoxaluria Treatment Revenue by Application (2017-2028)
8.3 Asia Pacific Primary Hyperoxaluria Treatment Market Size by Region
8.3.1 Asia Pacific Primary Hyperoxaluria Treatment Sales by Region (2017-2028)
8.3.2 Asia Pacific Primary Hyperoxaluria Treatment Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Primary Hyperoxaluria Treatment Market Size by Type
9.1.1 Latin America Primary Hyperoxaluria Treatment Sales by Type (2017-2028)
9.1.2 Latin America Primary Hyperoxaluria Treatment Revenue by Type (2017-2028)
9.2 Latin America Primary Hyperoxaluria Treatment Market Size by Application
9.2.1 Latin America Primary Hyperoxaluria Treatment Sales by Application (2017-2028)
9.2.2 Latin America Primary Hyperoxaluria Treatment Revenue by Application (2017-2028)
9.3 Latin America Primary Hyperoxaluria Treatment Market Size by Country
9.3.1 Latin America Primary Hyperoxaluria Treatment Sales by Country (2017-2028)
9.3.2 Latin America Primary Hyperoxaluria Treatment Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Primary Hyperoxaluria Treatment Market Size by Type
10.1.1 Middle East and Africa Primary Hyperoxaluria Treatment Sales by Type (2017-2028)
10.1.2 Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Type (2017-2028)
10.2 Middle East and Africa Primary Hyperoxaluria Treatment Market Size by Application
10.2.1 Middle East and Africa Primary Hyperoxaluria Treatment Sales by Application (2017-2028)
10.2.2 Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Application (2017-2028)
10.3 Middle East and Africa Primary Hyperoxaluria Treatment Market Size by Country
10.3.1 Middle East and Africa Primary Hyperoxaluria Treatment Sales by Country (2017-2028)
10.3.2 Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Oxthera
11.1.1 Oxthera Corporation Information
11.1.2 Oxthera Overview
11.1.3 Oxthera Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Oxthera Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Oxthera Recent Developments
11.2 Dicerna Pharmaceuticals
11.2.1 Dicerna Pharmaceuticals Corporation Information
11.2.2 Dicerna Pharmaceuticals Overview
11.2.3 Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Dicerna Pharmaceuticals Recent Developments
11.3 Allena Pharmaceuticals
11.3.1 Allena Pharmaceuticals Corporation Information
11.3.2 Allena Pharmaceuticals Overview
11.3.3 Allena Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Allena Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Allena Pharmaceuticals Recent Developments
11.4 Biocodex
11.4.1 Biocodex Corporation Information
11.4.2 Biocodex Overview
11.4.3 Biocodex Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Biocodex Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Biocodex Recent Developments
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Corporation Information
11.5.2 Alnylam Pharmaceuticals Overview
11.5.3 Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Alnylam Pharmaceuticals Recent Developments
11.6 Tecoland Corporation
11.6.1 Tecoland Corporation Corporation Information
11.6.2 Tecoland Corporation Overview
11.6.3 Tecoland Corporation Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Tecoland Corporation Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Tecoland Corporation Recent Developments
11.7 Zhejiang Tianxin Pharmaceutical
11.7.1 Zhejiang Tianxin Pharmaceutical Corporation Information
11.7.2 Zhejiang Tianxin Pharmaceutical Overview
11.7.3 Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Zhejiang Tianxin Pharmaceutical Recent Developments
11.8 Takeda Pharmaceuticals
11.8.1 Takeda Pharmaceuticals Corporation Information
11.8.2 Takeda Pharmaceuticals Overview
11.8.3 Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Takeda Pharmaceuticals Recent Developments
11.9 Wuxi Further Pharmaceutical
11.9.1 Wuxi Further Pharmaceutical Corporation Information
11.9.2 Wuxi Further Pharmaceutical Overview
11.9.3 Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Wuxi Further Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Primary Hyperoxaluria Treatment Industry Chain Analysis
12.2 Primary Hyperoxaluria Treatment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Primary Hyperoxaluria Treatment Production Mode & Process
12.4 Primary Hyperoxaluria Treatment Sales and Marketing
12.4.1 Primary Hyperoxaluria Treatment Sales Channels
12.4.2 Primary Hyperoxaluria Treatment Distributors
12.5 Primary Hyperoxaluria Treatment Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Primary Hyperoxaluria Treatment Industry Trends
13.2 Primary Hyperoxaluria Treatment Market Drivers
13.3 Primary Hyperoxaluria Treatment Market Challenges
13.4 Primary Hyperoxaluria Treatment Market Restraints
14 Key Findings in The Global Primary Hyperoxaluria Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の原発性高シュウ酸尿症治療市場インサイト及び予測（経口、静脈内、その他）(Global Primary Hyperoxaluria Treatment Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の原発性高シュウ酸尿症治療市場インサイト及び予測（経口、静脈内、その他）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp